MARKET

NTLA

NTLA

Intellia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.92
-1.39
-10.44%
After Hours: 11.92 0 0.00% 16:56 03/27 EDT
OPEN
13.02
PREV CLOSE
13.31
HIGH
13.02
LOW
11.91
VOLUME
619.33K
TURNOVER
--
52 WEEK HIGH
19.00
52 WEEK LOW
9.18
MARKET CAP
602.05M
P/E (TTM)
-5.6616
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NTLA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NTLA stock price target is 25.75 with a high estimate of 57.50 and a low estimate of 16.00.

EPS

NTLA News

More
  • Edited Transcript of NTLA earnings conference call or presentation 27-Feb-20 1:00pm GMT
  • Thomson Reuters StreetEvents · 5d ago
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Can CRISPR Therapeutics Double Your Money in 2020?
  • MotleyFool.com · 02/28 13:22
  • Oppenheimer Upgrades Intellia Therapeutics to Outperform
  • Benzinga · 02/28 10:49

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About NTLA

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
More

Webull offers kinds of Intellia Therapeutics Inc stock information, including NASDAQ:NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions.